Spero Therapeutics, Inc. Cash and Restricted Cash
Spero Therapeutics, Inc. (SPRO) had Cash and Restricted Cash of $52.55 million as of 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-05-10
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $52.55M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87.34M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.39M.
- 2016-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.37M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-03-31 | $52.55M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $87.34M 10-Q · filed 2018-05-10 |
| 2017-03-31 | $46.39M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $10.37M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |